|
Elizabeth S. Dodds Ashley, PharmD has received research support from Astellas, Cubist, Enzon, Pfizer, and Schering-Plough. Dr. Dodds Ashley was the co-principal investigator and the funds were paid to Duke, her institution. Additionally, Dr. Dodds-Ashley serves as a scientific consultant for Astellas, Enzon, Pfizer and Schering-Plough, and she is a speaker for Astellas, Cubist, Enzon, Pfizer, and Schering-Plough.
John R. Perfect, MD has received research support from Astellas, Enzon, Merck, Pfizer, and Schering-Plough. Dr. Perfect was the principal investigator and the funds were paid to Duke, his institution. Additionally, Dr. Perfect serves as a scientific consultant for Astellas, Enzon, Merck, Pfizer, and Schering-Plough and he serves on the scientific advisory board for Astellas, Enzon, Merck, Pfizer, and Schering-Plough.
Planning Committee Members: Karen Wetzel, American Academy of CME and Vesna Drenovac, RPh, MS, and David Christiansen, PhD, Vemco MedEd have disclosed that they have no relevant financial relationships with any commercial interests.
|